{"product_id":"e6-9b-bf-e9-9b-b7-e5-88-a9-e7-8f-a0-e5-8d-95-e6-8a-97-ef-bc-88tislelizumab-ef-bc-89","title":"Tevimbra（Tislelizumab）","description":"Tevimbra (Tislelizumab-jsgr) sold under the brand name \u003cstrong\u003e百泽安\u003c\/strong\u003e in china, is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.\r\n\r\nThe FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy that did not include a PD-1\/PD-L1 inhibitor.","brand":"BeiGene Biotechnology, China","offers":[{"title":"Default Title","offer_id":44797952589867,"sku":"RL2320301801","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-03-1610.png?v=1787022181","url":"https:\/\/xomeds.com\/products\/e6-9b-bf-e9-9b-b7-e5-88-a9-e7-8f-a0-e5-8d-95-e6-8a-97-ef-bc-88tislelizumab-ef-bc-89","provider":"XOMEDS","version":"1.0","type":"link"}